GLP-1 Treatment for Overweight: The Difference Between Semaglutide and Tirzepatide (Ozempic, Wegovy, Mounjaro)

An evidence-based guide from Vidacure

GLP-1–based medications have become some of the most studied and effective tools in the treatment of overweight and obesity. By influencing the body’s hunger and satiety systems, these medications can help patients achieve significant weight loss as part of a comprehensive medical treatment plan. In this article, we describe how semaglutide, found in Ozempic and Wegovy, and tirzepatide, found in Mounjaro, work in the body and what differentiates them.

How Do GLP-1 Medications Work in the Body?

GLP-1 is a natural hormone released in the intestine after a meal. It affects several key functions in the body. It increases the feeling of fullness and reduces hunger and cravings, while also slowing the rate at which the stomach empties. GLP-1 also stabilizes blood sugar levels by increasing insulin secretion and lowering levels of glucagon, a hormone that otherwise raises blood sugar. When these effects work together, they often lead to reduced energy intake, which can contribute to weight loss.

Semaglutide: Ozempic and Wegovy

Semaglutide is a GLP-1 agonist available in two different medications. Ozempic is approved for the treatment of type 2 diabetes but is sometimes used off-label for overweight. Clinical studies have shown that Ozempic can lead to an average weight loss of around 10–15 percent of body weight. Wegovy contains the same active substance but in higher doses and is specifically approved for the treatment of obesity and overweight. Studies show that Wegovy can result in approximately 15 percent weight loss. Semaglutide primarily affects appetite regulation and satiety, making it easier for many patients to reduce their calorie intake.

Tirzepatide: Mounjaro

Tirzepatide is a newer medication that differs from semaglutide by acting on two hormonal systems simultaneously. In addition to activating GLP-1, it also activates GIP, a hormone that enhances insulin secretion and further influences appetite regulation. This dual mechanism often results in greater weight loss than semaglutide. Mounjaro is approved for the treatment of obesity in Sweden. In clinical studies, tirzepatide has led to weight loss of around 20–22 percent of body weight, which is higher than what has been observed with semaglutide.

Comparison Between Semaglutide and Tirzepatide

Semaglutide, found in Ozempic and Wegovy, acts solely through GLP-1, while tirzepatide in Mounjaro affects both GLP-1 and GIP. Wegovy and Mounjaro are approved for weight management, while Ozempic is approved for diabetes treatment. The appetite-reducing effect is strong with semaglutide but even more pronounced with tirzepatide, which is reflected in clinical results showing approximately 10–15 percent weight loss with semaglutide and around 20–22 percent with tirzepatide. Both medications are administered as weekly injections.

Why Does Tirzepatide Often Work Better?

The dual effect on both GLP-1 and GIP provides the body with a stronger satiety signal and more efficient blood sugar regulation. This can lead to a more noticeable reduction in hunger, more stable energy levels, and a more consistent calorie deficit. Together, these mechanisms contribute to tirzepatide often producing greater overall weight loss than semaglutide in clinical studies.

Are GLP-1 Medications Right for Everyone?

GLP-1 treatment is not suitable for everyone. Treatment with semaglutide or tirzepatide always requires a medical assessment, regular monitoring of effects and side effects, and should be combined with lifestyle support. Vidacure follows evidence-based guidelines and adheres to regulatory standards to ensure that all information is neutral, accurate, and safe for patients.

Side effects and price differences

Both medications work on incretin hormones and therefore share many gastrointestinal side effects. However, the frequency and intensity differ slightly.

Semaglutide (Wegovy)

Semaglutide’s side effects are well-documented and mostly gastrointestinal. The most common include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. These effects are usually strongest during dose escalation and tend to decrease over time. Some patients experience acid reflux or bloating. Rare but serious risks include gallbladder issues and pancreatitis.

Tirzepatide (Mounjaro)

Tirzepatide has a similar side-effect profile but can cause slightly more gastrointestinal symptoms at higher doses, likely due to its dual activation of both GLP-1 and GIP receptors. Nausea, diarrhea, and decreased appetite are common. Some patients report fatigue or mild injection-site reactions. As with semaglutide, gallbladder issues and pancreatitis are rare but possible.

Price comparison

In many markets, Wegovy costs slightly less than Mounjaro. Mounjaro is often more expensive than Wegovy. In Sweden, Mounjaro is approved for obesity, but pricing is still high and it is not reimbursed.

Summary

Semaglutide, found in Ozempic and Wegovy, and tirzepatide, found in Mounjaro, influence the body’s hunger and satiety systems in different ways. Wegovy and Mounjaro are approved for weight management, while Ozempic is approved for diabetes. Tirzepatide has shown greater weight-loss effects in studies due to its dual mechanism of action. Regardless of medication, treatment requires medical follow-up and should always be combined with lifestyle support for the best results.

Sources